wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 1 - 50 of 286.
1 2 3 4 5 6 Next »

Medicine/Pharmacology - Life Sciences
18.01.2017
Unveiling the biology behind nonalcoholic fatty liver disease
Unveiling the biology behind nonalcoholic fatty liver disease
EPFL scientists have discovered a new biological mechanism behind nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease covers a range of diseases that result from fat accumulation in the liver, but not as a result of alcohol abuse. Fat buildup can lead to liver inflammation, scarring and irreversible damage, such as cirrhosis and liver failure.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Computer Science/Telecom
17.01.2017
Work in the year 2050
Work in the year 2050
How will digitalisation, artificial intelligence and robotics change the world of work? This question was discussed by numerous experts from business and academia at the ‘Global Talent Summit' before an audience of more than 300 in the Audi Max room at ETH Zurich.
Chemistry - Physics/Materials Science
17.01.2017
An ultrafast light source in a laboratory format
An ultrafast light source in a laboratory format
Researchers at ETH Zurich and the University of Geneva have succeeded for the first time in using a laboratory X-ray source to demonstrate how two highly fluorinated molecules change within a few quadrillionths of a second, or femtoseconds. In nature, some processes occur so quickly that even the blink of an eye is very slow in comparison.
Social Sciences - Earth Sciences
13.01.2017
Bhutan's happiness stems from its hydropower too
Bhutan's happiness stems from its hydropower too
EPFL researchers are supporting this Himalayan country's efforts to expand its hydropower capacity. At a time when dams in Switzerland are up for sale, another small mountainous country intent on preserving its natural environment is looking to further tap into its hydroelectric potential.
Environment/Sustainable Development - Media
12.01.2017
Peter Messerli named co-chair of UN Global Sustainable Development Report
Peter Messerli named co-chair of UN Global Sustainable Development Report
Media releases, information for representatives of the media Media Relations (E) Peter Messerli, Professor of Sustainable Development at the University of Bern, has been selected as co-chair to lead
Physics/Materials Science - Chemistry
12.01.2017
Creating the tiniest structures
Creating the tiniest structures
Nanotechnology is regarded as the key technology of the 21st century, delivering the fundamental methods which allow objects just a few hundred nanometres in size to be produced in any required shape.
Physics/Materials Science - Environment/Sustainable Development
10.01.2017
Summer heat for the winter
Summer heat for the winter
Can thermal solar energy be stored until wintertime? Within a European research consortium Empa scientists and their colleagues have spent four years studying this question by pitting three different techniques against each other.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Medicine/Pharmacology - Physics/Materials Science
03.01.2017
Looking back at 2016 (2/2)
Looking back at 2016 (2/2)
Slowing the aging process, improving data security, enabling paraplegics to walk again, transporting vaccines at room temperature to warm countries, creating jobs with the CHF 400 million raised by spin-offs - those are just some of the many areas where EPFL scientists have made a lasting contribution.
Chemistry - Physics/Materials Science
03.01.2017
Chemically Modified Insulin Is Available More Quickly
Chemically Modified Insulin Is Available More Quickly
Replacing a hydrogen atom by an iodine atom in insulin, the hormone retains its efficacy but is available more rapidly to the organism. Researchers at the University of Basel were able to predict this effect based on computer simulations and then confirm it with experiments. Insulin is formed in the pancreas and regulates the blood glucose level.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Microtechnics/Electroengineering - Computer Science/Telecom
23.12.2016
A world record followed by a world premiere
A world record followed by a world premiere
A new world record for acceleration, a timber roof built by construction robots, and a unique competition for people with disabilities: in 2016, research and campus life at ETH Zurich were dominated by innovation and premieres.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Environment/Sustainable Development
23.12.2016
Fighting cholera by predicting how its spreads
Fighting cholera by predicting how its spreads
In October, EPFL and Médecins Sans Frontières joined forces in an unprecedented effort to predict how the cholera epidemic in Haiti will spread.
Psychology - Medicine/Pharmacology
22.12.2016
Helping pays off: People who care for others live longer
Older people who help and support others live longer. These are the findings of a study published in the journal ‘Evolution and Human Behavior', conducted by researchers from the University of Basel, Edith Cowan University, the University of Western Australia, the Humboldt University of Berlin, and the Max Planck Institute for Human Development in Berlin.
Medicine/Pharmacology
22.12.2016
Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with haemophilia A an
Civil Engineering/Traffic Engineering - Chemistry
21.12.2016
A unique additive for the ideal concrete
A unique additive for the ideal concrete
Whether it's for drying time, hardness, or uniformity, a new additive developed at EPFL can give concrete, mortar, and cement the desired consistency, all in one shot.
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Environment/Sustainable Development - Earth Sciences
20.12.2016
Three months in the Antarctic to unlock the secrets of our climate
Three months in the Antarctic to unlock the secrets of our climate
The Antarctic Circumnavigation Expedition (ACE), the first project run by the Swiss Polar Institute (SPI), will set sail this evening from South Africa.
Environment/Sustainable Development - Life Sciences
20.12.2016
University of Zurich to become global center for biodiversity research
University of Zurich to become global center for biodiversity research
Prof. Michael Schaepman, PhD Department of Geography University of Zurich Phone +41 44 635 51 60 E-mail Prof. Bernhard Schmid, PhD Institute of Evolutionary Biology and Environmental Studies
Life Sciences - Administration/Government
20.12.2016
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Architecture - Computer Science/Telecom
19.12.2016
The lab that's betting on low-tech
From the Saint Loup Chapel in Pompaples to the soon-to-be-completed Vidy Theatre Pavilion in Lausanne, the lab run by Yves Weinand is developing new innovations based on an age-old material: wood.
Business/Economics
16.12.2016
Switzerland ratifies Croatia protocol
Bern, 16.12.2016 - Switzerland has ratified the protocol extending the free movement of persons to Croatia.
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Environment/Sustainable Development - Earth Sciences
16.12.2016
A month at sea expanding her horizons and knowledge
A month at sea expanding her horizons and knowledge
EPFL student Oriane Etter and 48 other students from universities around the globe just completed the ACE Maritime University.
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Environment/Sustainable Development
16.12.2016
A drone that flies (almost) like a bird
A drone has been equipped with feathers to increase its precision during flight. The bio-inspired device can spread or close its wings while flying, making it easier to maneuver and more resistant in high winds.
Administration/Government
15.12.2016
Physics/Materials Science
15.12.2016
The All-In-One outdoor sleep system for
The All-In-One outdoor sleep system for
As of today the All-In-One sleep system developed by the «Polarmond» start-up company is ready for delivery.
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Environment/Sustainable Development - Earth Sciences
14.12.2016
The open-air researcher
The open-air researcher
Atmospheric scientist Julia Schmale is starting out, together with more than fifty other researchers, on a three-month research cruise around the Antarctic.
Administration/Government - Careers/Employment
14.12.2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
Start-ups linked to EPFL raised almost CHF 400 million this year - that's over 50% more than in 2014, the last record year.
Physics/Materials Science
13.12.2016
A golden era for
A golden era for "fashionistas"
The gold thread developed at Empa is having extensive repercussions. Hot on the heels of a dessous collection being refined with the new technology, scarves and luxury watches are now also available.
Chemistry - Physics/Materials Science
12.12.2016
In the focus of the protons
In the focus of the protons
In several laboratories at the Paul Scherrer Institute PSI, researchers work with radioactive substances that eventually should aid in the diagnosis and treatment of cancer or metabolic diseases - bu
Medicine/Pharmacology
12.12.2016
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care Lucentis monotherapy , Recent Lucentis EU approval in new choroidal neovascularization (CNV)  indication
Medicine/Pharmacology - Administration/Government
12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tablet
Medicine/Pharmacology
12.12.2016
EPFL spinoff QGel raises 12 million dollars from private investors
EPFL spinoff QGel raises 12 million dollars from private investors
QGel is a startup that makes a synthetic gel for growing cells as if they were in the human body. This breakthrough enhances the reliability of research into anti-cancer drugs.
Physics/Materials Science
09.12.2016
Eight professors appointed at ETH Zurich
Eight professors appointed at ETH Zurich
Upon application of ETH President Lino Guzzella the ETH Board appointed a total of eight professors and awarded the title of professor to one individual.
Medicine/Pharmacology
09.12.2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone   LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de
Business/Economics - Careers/Employment
09.12.2016
Medicine/Pharmacology - Event
08.12.2016
The R. Geigy Foundation honours efforts to overcome ’neglected tropical diseases
Giovanna Raso and Jean Coulibaly are the awardees of the R. Geigy-Award 2016 and will share a CHF 20,000 prize in honour of their efforts to fight neglected helminth infections in West Africa.
1 2 3 4 5 6 Next »